Observation on the therapeutic effect of Sheng Mai San mixed Jiawei Sheng Xian Tang on heart failure with reduced ejection fraction of Qi deficiency blood stasis type

doi:10.11958/20251179

Abstract

Abstract:

Objective To investigate the therapeutic effect of Sheng Mai San mixed Jiawei Sheng Xian Tang on patients with heart failure with reduced ejection fraction (HFrEF) of Qi deficiency blood stasis type, and its impact on the immune inflammatory response of patients. Methods Ninety patients with HFrEF of Qi deficiency blood stasis type were selected and divided into two groups according to the treatment plan. Patients of the conventional group (42 cases) took sacubitril/valsartan sodium tablets orally. Patients of the combined group (48 cases) were treated with Sheng Mai San combined with Jiawei Sheng Xian Tang on the basis of the conventional group, one dose per day, and divided it in two servings used in the morning and evening. The symptoms of the patients were evaluated by using traditional Chinese medicine (TCM) syndrome score before and after the treatment respectively. Echocardiography technology was used to measure the left ventricular end-diastolic diameter (LVEDD) and left ventricular ejection fraction (LVEF). Enzyme-linked immunosorbent assay was used to detect pentaggrin 3 (PTX3), tumor necrosis factor -α (TNF-α), galectin-3 (Gal-3), interleukin (IL) -8, IL-6, IL-33 and angiotensin Ⅱ (Ang Ⅱ). N-terminal pro-brain natriuretic peptide (NT-proBNP) was detected by immunofluorescence analysis. The therapeutic effect was evaluated based on the symptoms and the New York Heart Association (NYHA) cardiac function classification in the United States. Results After treatment, the levels of TCM syndrome scores, LVEDD, TNF-α, PTX3, IL-8, IL-6, IL-33, NT-proBNP, Gal-3 and AngⅡ decreased in both groups, and those in the combined group were lower than those in the conventional group (P<0.05). The LVEF increased, and which were higher in the combined group than those of the conventional group (P<0.05). After the treatment, the total effective rate of the combined group was higher than that of the conventional group (P<0.05). Conclusion The Sheng Mai San mixed Jiawei Sheng Xian Tang as adjuvant therapy can effectively reduce the levels of immune inflammatory cytokines in HFrEF patients of Qi deficiency blood stasis type, improve their clinical symptoms and enhance therapeutic effect.

Key words: heart failure, Sheng Mai San, Sheng Xian Tang, Qi deficiency blood stasis, inflammation, left ventricular ejection fraction

CLC Number:

R541.6

Figures/Tables 5

References 20

[1]	SAVARESE G, STOLFO D, SINAGRA G, et al. Heart failure with mid-range or mildly reduced ejection fraction[J]. Nat Rev Cardiol, 2022, 19(2):100-116. doi:10.1038/s41569-021-00605-5.
[2]	NIU C Y, YANG S F, OU S M, et al. Sacubitril/Valsartan in patients with heart failure and concomitant end-stage kidney disease[J]. J Am Heart Assoc, 2022, 11(18):e026407. doi:10.1161/JAHA.122.026407.
[3]	赵桂芳, 翟大娟, 谈金强, 等. 活心丸联合沙库巴曲缬沙坦对射血分数降低型慢性心力衰竭患者的临床效果观察[J]. 中外女性健康研究, 2024(4):53-55.
	ZHAO G F, ZHAI D J, TAN J Q, et al. Observation on the clinical effect of huoxin pills combined with sacubitril/valsartan on patients with chronic heart failure with reduced ejection fraction[J]. Women's Health Research, 2024(4):53-55.
[4]	李光智, 林称心, 王转转. 生脉散合血府逐瘀汤加减方对气阴两虚、心血瘀阻型慢性心力衰竭患者相关疗效性指标及NT-proBNP ACR的影响[J]. 广州中医药大学学报, 2023, 40(6):1349-1354.
	LI G Z, LIN C X, WANG Z Z, et al. Effects of modified formula of Shengmai Powder plus Xuefu Zhuyu Decoction on the efficacy indicators and NT-proBNP and albumin-creatinine ratio in patients with chronic heart failure of Qi-Yin deficiency and heart-blood stasis obstruction type[J]. Journal of Guangzhou University of Traditional Chinese Medicine, 2023, 40(6):1349-1354. doi:10.13359/j.cnki.gzxbtcm.2023.06.007.
[5]	田志广. 加味升陷汤辅治慢性心力衰竭临床观察[J]. 实用中医药杂志, 2024, 40(2):254-256.
	TIAN Z G. Clinical observation on the adjuvant treatment of chronic heart failure with modified shengxian decoction[J]. Journal of Practical Traditional Chinese Medicine, 2024, 40(2):254-256.
[6]	中华医学会心血管病学分会心力衰竭学组, 中国医师协会心力衰竭专业委员会, 中华心血管病杂志编辑委员会. 中国心力衰竭诊断和治疗指南2018[J]. 中华心血管病杂志, 2018, 46(10):760-789.
	Heart Failure Group of Chinese Society of Cardiology of Chinese Medical Association, Chinese Heart Failure Association of Chinese Medical Doctor Association, Editorial Board of Chinese Journal of Cardiology. Chinese guidelines for the diagnosis and treatment of heart failure 2018[J]. Chin J Cardiol, 2018, 46(10):760-789. doi:10.3760/cma.j.issn.0253-3758.2018.10.004.
[7]	郑筱萸. 中药新药临床研究指导原则:试行[M]. 北京: 中国医药科技出版社, 2002:77-85.
	ZHENG X Y. Guiding principles for clinical research of new chinese medicines:trial implementation[M]. Beijing: China Medical Science Press, 2002:77-85.
[8]	郭吉雷. 沙库巴曲缬沙坦治疗伴慢性射血分数降低心力衰竭的血液透析患者的效果评价[J]. 中国实用医药, 2024, 19(19):17-20.
	GUO J L. Study on the effect of sacubitril-valsartan in the treatment of hemodialysis patients with chronic heart failure with reduced ejection fraction[J]. China Practical Medical, 2024, 19(19):17-20. doi:10.14163/j.cnki.11-5547/r.2024.19.004.
[9]	张世威, 沈志方, 常国栋. 芪苈强心胶囊辅助沙库巴曲缬沙坦钠治疗射血分数降低型慢性心力衰竭患者的临床疗效[J]. 四川生理科学杂志, 2024, 46(6):1226-1229.
	ZHANG S W, SHEN Z F, CHANG G D. Clinical efficacy of qiliqiangxin capsule supplemented with Sacubitril valsartan sodium in the treatment of patients with chronic heart failure with reduced ejection fraction[J]. Sichuan Journal of Physiological Sciences, 2024, 46(6):1226-1229.
[10]	车驰, 田鑫, 彭双凤, 等. 射血分数降低型心力衰竭中医证型与BNP、CA125表达水平及心功能的相关性分析[J]. 辽宁中医杂志, 2024, 51(2):86-90.
	CHE C, TIAN X, PENG S F, et al. correlation analysis of traditional chinese medicine syndrome types,levels of BNP and CA125 and cardiac function in heart failure with reduced ejection fraction[J]. Liaoning Journal of Traditional Chinese Medicine, 2024, 51(2):86-90. doi:10.13192/j.issn.1000-1719.2024.02.021.
[11]	耿新冉, 杨硕. 生脉散治疗慢性心力衰竭的临床应用现状[J]. 中国临床药理学杂志, 2024, 40(22):3328-3332.
	GENG X R, YANG S. Current status of clinical application of Shengmaisan in the treatment of chronic heart[J]. Chin J Clin Pharmacol, 2024, 40(22):3328-3332. doi:10.13699/j.cnki.1001-6821.2024.22.022.
[12]	李建华, 王明珠, 姚磊, 等. 加味升陷汤联合沙库巴曲缬沙坦钠片治疗慢性射血分数降低的心力衰竭病人的临床疗效观察[J]. 中西医结合心脑血管病杂志, 2022, 20(11):1946-1949,1958.
	LI J H, WANG M Z, YAO L, et al. Clinical observation of Jiawei Shengxian Decoction combined with Entresto in the treatment of chronic heart failure patients with reduced ejection fraction[J]. Chinese Journal of Integrative Medicine on Cardio/Cerebrovascular Disease, 2022, 20(11):1946-1949,1958. doi:10.12102/j.issn.1672-1349.2022.11.004.
[13]	许丁, 赵慧慧, 周淑文, 等. 沙库巴曲缬沙坦与缬沙坦治疗射血分数降低的心力衰竭的临床疗效及其对血清肿瘤坏死因子α、半乳糖凝集素3、基质金属蛋白酶9水平的影响[J]. 实用心脑肺血管病杂志, 2023, 31(1):107-111.
	XU D, ZHAO H H, ZHOU S W, et al. Clinical efficacy of Sacubitril/Valsartan and Valsartan in the teatment of HFrEF and their effect on serum levels of TNF-α,Gal-3,MMP-9[J]. Pract J Cardiac Cereb Pneum Vasc Dis, 2023, 31(1):107-111. doi:10.12114/j.issn.1008-5971.2022.00.188.
[14]	李汶玲, 陈娇娇. 血清前白蛋白和正五聚蛋白3水平对AMI患者PCI术后心力衰竭发生的预测价值[J]. 新疆医科大学学报, 2023, 46(5):643-647.
	LI W L, CHEN J J. Predictive value of serum prealbumin and pentraxin 3 levels for occurrence of heart failure in AMI patients after PCI[J]. Journal of Xinjiang Medical University, 2023, 46(5):643-647. doi:10.3969/j.issn.1009-5551.2023.05.013.
[15]	CHAAR D, DUMONT B, VULESEVIC B, et al. Neutrophils pro-inflammatory and anti-inflammatory cytokine release in patients with heart failure and reduced ejection fraction[J]. ESC Heart Fail, 2021, 8(5):3855-3864. doi:10.1002/ehf2.13539.
[16]	XIANG N, LIAO H, ZHAI Z, et al. Expression and significance of inflammatory reactions mediated by the IL-33/ST2 signaling pathway in the serum of heart failure patients[J]. Am J Transl Res, 2021, 13(7):8247-8252.
[17]	ABUBAKAR M, RASOOL H F, JAVED I, et al. Comparative roles of IL-1,IL-6,IL-10,IL-17,IL-18,1L-22,IL-33,and IL-37 in various cardiovascular diseases with potential insights for targeted immunotherapy[J]. Cureus, 2023, 15(7):e42494. doi:10.7759/cureus.42494.
[18]	张学飞, 张甜田. miR-146a、Gal-3在射血分数保留型心力衰竭患者中的表达及与心室重构的相关性分析[J]. 医学理论与实践, 2024, 37(7):1187-1189.
	ZHANG X F, ZHANG T T. Expression of miR-146a and Gal-3 in patients with heart failure with preserved ejection fraction and correlation analysis with ventricular remodeling[J]. J Med Theor ＆ Prac, 2024, 37(7):1187-1189. doi:10.19381/j.issn.1001-7585.2024.07.039.
[19]	吴政燮, 韩才均, 崔海霞, 等. IL-6、CRP、NLR和NT-proBNP对老年心力衰竭合并肺炎的诊断价值[J]. 检验医学与临床, 2024, 21(9):1250-1253,1258.
	WU Z X, HAN C J, CUI H X, et al. Expression and diagnostic value of IL-6,CRP,NLR and NT-proBNP in elderly patients with heart failure complicated by pneumonia[J]. Lab Med Clin, 2024, 21(9):1250-1253,1258. doi:10.3969/j.issn.1672g9455.2024.09.013.
[20]	何文凤, 薛成, 郑健康, 等. 参松养心胶囊联合沙库巴曲缬沙坦治疗阵发性心房颤动合并慢性心力衰竭对hs-CRP、BNP、AngⅡ及心功能的影响[J]. 中华中医药学刊, 2024, 42(6):95-98.
	HE W F, XUE C, ZHENG J K, et al. Effects of Shensong Yangxin Capsule combined with Sacubatro Valsartan on hs-CRP,BNP,Ang Ⅱ and cardiac function in treatment of paroxysmal atrial fibrillation complicated with chronic heart failure[J]. Chinese Archives of Traditional Chinese Medicine, 2024, 42(6):95-98. doi:10.13193/j.issn.1673-7717.2024.06.018.

组别	n	性别（男/女）	年龄/岁	NYHA心功能分级（Ⅱ/Ⅲ/Ⅳ）
常规组	42	22/20	64.99±9.28	17/20/5
联合组	48	23/25	64.51±9.75	19/21/8
χ²或t		0.179	0.238	0.430

组别	n	性别（男/女）	年龄/岁	NYHA心功能分级（Ⅱ/Ⅲ/Ⅳ）
常规组	42	22/20	64.99±9.28	17/20/5
联合组	48	23/25	64.51±9.75	19/21/8
χ²或t		0.179	0.238	0.430

组别	n		呼吸困难						疲劳无力
组别	n		治疗前		治疗后		t		治疗前		治疗后		t
常规组	42		4.88±0.96		2.08±0.59		16.104^＊＊		5.01±0.79		2.52±0.74		14.908^＊＊
联合组	48		4.92±1.06		1.55±0.41		20.543^＊＊		5.06±0.81		2.09±0.66		19.694^＊＊
t			0.187		4.997^＊＊				0.296		2.914^＊
组别		咳嗽						身体肿胀
组别		治疗前		治疗后		t		治疗前		治疗后		t
常规组		3.69±1.08		2.28±0.61		7.367^＊＊		3.20±0.78		2.03±0.56		7.897^＊＊
联合组		3.77±1.12		1.95±0.63		9.812^＊＊		3.24±0.74		1.78±0.52		11.184^＊＊
t		0.344		2.516^＊				0.249		2.195^＊

组别	n		呼吸困难						疲劳无力
组别	n		治疗前		治疗后		t		治疗前		治疗后		t
常规组	42		4.88±0.96		2.08±0.59		16.104^＊＊		5.01±0.79		2.52±0.74		14.908^＊＊
联合组	48		4.92±1.06		1.55±0.41		20.543^＊＊		5.06±0.81		2.09±0.66		19.694^＊＊
t			0.187		4.997^＊＊				0.296		2.914^＊
组别		咳嗽						身体肿胀
组别		治疗前		治疗后		t		治疗前		治疗后		t
常规组		3.69±1.08		2.28±0.61		7.367^＊＊		3.20±0.78		2.03±0.56		7.897^＊＊
联合组		3.77±1.12		1.95±0.63		9.812^＊＊		3.24±0.74		1.78±0.52		11.184^＊＊
t		0.344		2.516^＊				0.249		2.195^＊

组别	n	LVEF/%			LVEDD/mm
组别	n	治疗前	治疗后	t	治疗前	治疗后	t
常规组	42	31.16±7.38	44.20±10.43	3.571^＊	63.14±14.07	56.42±11.64	2.385^＊
联合组	48	31.04±7.25	49.88±10.95	6.336^＊＊	63.36±14.21	50.87±11.31	4.765^＊＊
t		0.078	2.519^＊		0.074	2.291^＊